A series of novel analogs of water soluble pterostilbene amino acid bearing carbonates were synthesized, which show activities in treating a non-alcoholic fatty liver disease and a nonalcoholic steatohepatitis (NASH).

Disclosed herein are naphthoquinone derivative compounds of the formula shown below, compositions thereof, and methods of using such compounds and compositions for treating or suppressing oxidative stress disorders and/or neurodegenerative disorders and/or for inhibiting ferroptosis.

##STR00001##

Several biological targets have been implicated in the pathogenesis of lung, liver, renal and prostrate fibrotic proliferative diseases. While cannabinoid receptor-mediated signaling has emerged as a novel signaling pathway regulating fibrogenesis and inflammation, the present invention relates generally to biologically active compounds capable of interacting with one or more biological targets including the CB1 and/or the CB2 cannabinoid receptors, and comprise of neutral antagonists, neutral-peripheral antagonists, peripheral antagonists/inverse-agonists, compounds with mixed properties including CB1 antagonist/CB2 agonist properties, and allosteric properties for treating fibrosis of the liver, lung, kidney and the prostrate, and inflammatory conditions, including benign prostatic hyperplasia. Also, aspects of the invention are concerned with imidazoles, triazoles, thiazoles, oxazoles, pyrazoles and dihydropyrazoles containing the 4-(λ2-azaneyl)thiomorpholine 1,1-dioxide group or the 4λ2-thiomorpholine 1,1-dioxide group.

Disclosed in the present application are a compound of general formula (I) capable of being used as a CDK kinase (in particular, CDK4/6 kinase) inhibitor, and a salt thereof, wherein all variates are defined as the present text. The compound can be used for treating or preventing diseases such as cancer. The present application further relates to a pharmaceutical composition comprising the compound of formula (I).

The present disclosure relates to a boron compound applicable to an organic light-emitting diode and an organic light-emitting diode comprising same. More specifically, the present disclosure relates to a boron compound represented by any one of Chemical Formulas A to D and an organic light-emitting diode comprising same, wherein Chemical Formulas A to D are as defined in the description.

The compound represented by formula (1):

##STR00001##

wherein symbols are as defined in the description, provides an organic electroluminescence device having a device performance further improved.

Provided is an organic light emitting device including a light emitting layer comprising a compound of Chemical Formula 1 and a first organic material layer comprising a compound of Chemical Formula 2:

##STR00001## wherein: Cy1 to Cy5 are each independently one selected from among a substituted or unsubstituted: aromatic hydrocarbon ring, aliphatic hydrocarbon ring, and aromatic hetero ring, or a ring in which two or more rings selected from the above group are fused, one or more of Cy1 to Cy5 are a ring of Chemical Formula 1-A:

##STR00002## one to three of a* to d* are a position fused to or linked to Chemical Formula 1;

##STR00003## L1 to L3 are each independently a direct bond or a substituted or unsubstituted: arylene or divalent heterocyclic group; and Ar1 and Ar2 are each independently a substituted or unsubstituted: aryl or heterocyclic group.

The disclosure is directed to compounds of Formula I

##STR00001##

pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

An intermediate is provided herein, and it has the structure shown in the formula (1) as follows:

##STR00001##

formula (1). In the formula (1), R.sub.1 is —Cl, —Br, —I, —OSO.sub.2CF.sub.3, —B(OH).sub.2, or

##STR00002##

R.sub.2 is —F, —.sup.18F, —Cl, —Br, —I, —SnMe.sub.3, —SnBu.sub.3, —B(OH).sub.2, or

##STR00003##

and A is a chiral auxiliary.

A compound, Ir(L.sub.A).sub.m(L.sub.B).sub.3-m, having a structure of Formula I,

##STR00001##

is provided. In Formula I, each of moiety A and moiety C is independently a 5- or 6-membered ring or a polycyclic fused ring system comprising 5- or 6-membered rings; moiety B is a 5-membered heterocyclic ring; Z.sup.1, Z.sup.2, and Z.sup.3 are C or N; m is 1 or 2; at least one of R.sup.1, R.sup.2, R.sup.3, R.sup.4 has a structure of Formula II,

##STR00002##

or is a 5-membered heterocyclic ring; each of X.sup.1, X.sup.2, X.sup.3, X.sup.4, and X.sup.5 is CR or N; each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.A, R.sup.B, R.sup.C, and R is hydrogen or a General Substituent; at least one of R.sup.1a, R.sup.2a, R.sup.3a, R.sup.4a, R.sup.5a is cycloalkyl, alkyl, silyl, germyl, deuterated variants thereof, fluorinated variants thereof, and combinations thereof. Formulations, OLEDs, and consumer products containing the compound are also provided.